Benzinga · Aug 25, 2026
TD Cowen Maintains Buy on Zoetis, Lowers Price Target to $94
TD Cowen analyst Steve Scala maintains Zoetis (NYSE:ZTS) with a Buy and lowers the price target from $104 to $94.
NYSE · ZTS
Zoetis Inc.
Healthcare · Drug Manufacturers - Specialty & Generic
$77.34
Up+$2.32 (+3.09%)
Updated Aug 31, 2026, 7:38 AM
SID Score
5.8/10
Composite research score
Smart Money
54/100
Neutral
- Market cap
- 51.85B
- P/E ratio
- 19.66
- Dividend yield
- 2.59%
- 52-week range
- $71.00 – $132.49
- Volume
- 4.85M
- Avg. volume
- 4.62M
Price performance
ZTS price history
1M range · 20 trading sessions · Daily adjusted prices
ZTS closed at $77.34 after 20 trading sessions, up 0.31% for the selected period.
- Last close
- $77.34
- Period change
- +0.31%
- Period low
- $72.66
- Period high
- $77.73
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 28, 2026 | $75.20 | $77.71 | $75.20 | $77.34 | 4.85M |
| Aug 27, 2026 | $76.57 | $76.9112 | $74.93 | $75.02 | 3.97M |
| Aug 26, 2026 | $76.82 | $78.7499 | $76.55 | $77.52 | 4.85M |
| Aug 25, 2026 | $76.65 | $77.45 | $75.88 | $77.29 | 3.48M |
| Aug 24, 2026 | $77.59 | $78.20 | $76.4805 | $77.17 | 4.07M |
| Aug 21, 2026 | $75.29 | $78.59 | $75.18 | $77.73 | 5.05M |
| Aug 20, 2026 | $76.10 | $77.2946 | $74.935 | $75.02 | 3.92M |
| Aug 19, 2026 | $74.63 | $77.46 | $74.62 | $76.68 | 5.22M |
| Aug 18, 2026 | $73.75 | $74.48 | $72.88 | $73.96 | 4.03M |
| Aug 17, 2026 | $73.10 | $73.10 | $71.00 | $72.97 | 6.55M |
| Aug 14, 2026 | $75.52 | $76.37 | $73.61 | $73.79 | 4.46M |
| Aug 13, 2026 | $74.09 | $75.84 | $73.01 | $75.84 | 7.35M |
| Aug 12, 2026 | $74.39 | $74.39 | $71.99 | $73.54 | 7.19M |
| Aug 11, 2026 | $74.24 | $75.83 | $74.095 | $75.35 | 4.13M |
| Aug 10, 2026 | $72.40 | $74.98 | $71.45 | $74.83 | 9.61M |
| Aug 7, 2026 | $77.92 | $79.25 | $72.19 | $72.66 | 12.78M |
| Aug 6, 2026 | $78.82 | $79.60 | $73.71 | $77.27 | 17.85M |
| Aug 5, 2026 | $76.10 | $76.6499 | $72.98 | $74.39 | 10.18M |
| Aug 4, 2026 | $76.05 | $76.42 | $74.99 | $76.04 | 7.6M |
| Aug 3, 2026 | $79.31 | $80.17 | $76.85 | $77.10 | 5.06M |
Latest ZTS news
The latest Smart Investors Daily articles mentioning ZTS.
Stock researchCompany · Overview
ZTS research
Overview
Company profile and research snapshot.
Company profile
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Hold
- Average target
- $157.80
- Implied upside
- —
- Analysts
- 15
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 25, 2026 | TD Cowen | Buy | — |
| Aug 20, 2026 | Stifel | Hold | — |
| Aug 11, 2026 | Citigroup | Buy | — |
| Aug 11, 2026 | BNP Paribas | Outperform | — |
| Aug 10, 2026 | Piper Sandler | Neutral | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 20, 2026
Stifel Maintains Hold on Zoetis, Lowers Price Target to $80
Stifel analyst Jonathan Block maintains Zoetis (NYSE:ZTS) with a Hold and lowers the price target from $85 to $80.
Yahoo · Aug 19, 2026
Zoetis (ZTS) Stock Still Looks Cheap After a 62% Slide
Zoetis stock has had a tough run over the last few years, yet the current valuation checks suggest the shares may now be pricing in a lot of that bad news. After a prolonged slide, the question is whether the current market price properly reflects Zoetis' earnings power and risks. Over the past 5 years, Zoetis shareholders have seen the share price decline about 61.8%, which points to a significant reset in expectations. Recent investor focus is on how competition and softer pet care...
Yahoo · Aug 19, 2026
Is Zoetis’ Lowered 2026 Outlook and Simparica Trio EUA Altering The Investment Case For Zoetis (ZTS)?
Zoetis recently received an Emergency Use Authorization from the U.S. FDA for its Simparica Trio chewable to treat life-threatening New World screwworm infestations in dogs and puppies, while also appointing experienced healthcare executive Jay Saccaro as its new Chief Financial Officer and Chief Operating Officer. At the same time, Zoetis lowered its full-year 2026 revenue and earnings guidance, signaling a more cautious outlook even as it expands the clinical reach of one of its flagship...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
